| Steven Cohen's SAC Capital Discloses New XenoPort Stake Market Folly submits:Due to activity on May 14th, 2010, Steven Cohen's hedge fund firm SAC Capital has disclosed a new position in XenoPort (XNPT). As per a 13G filed with the SEC, SAC Capital shows a 6.0% ownership stake in the company with 1,819,228 shares. Again, this is a new position for the fund as it did not show ownership in its previous portfolio disclosure as of March 31st, 2010.Please also keep in mind that SAC is a trading oriented firm and moves in and out of positions much quicker than the fundamental hedge funds we typically track. Of the prominent hedge funds we cover, we've only seen one other firm previously own shares of XNPT. Lee Ainslie's firm had a position in XenoPort, but Maverick Capital just sold out in the first quarter. Regarding other recent portfolio activity from Steven Cohen's firm, we saw that it raised its stake in Inspire Pharma (ISPH) and updated its position in The Talbots (TLB).Complete Story » seekingalpha.com |
Should Gilead Sciences Declare a Dividend? eChristian Investing submits:Investors in Gilead Sciences (GILD) have had quite a run over the past decade. From 1996 through 2008, GILD shares posted gains every single year. During that same 13-year period, the Dow Jones index only posted gains in 8 years. The other 5 years the Dow posted some significant losses. Investors who purchased GILD shares at the beginning of 1996 have experienced a phenomenal 5,922% return. It seemed like the stock could only climb higher each year and the stock split four times from 2001-2006.Complete Story » seekingalpha.com |
A Reintroduction to Savient's Krystexxa Rockford Coscia submits: On September 17, Savient's (SVNT) Krystexxa (pegloticase) faces what could be the end of a tumultuous journey to approval. Krystexxa has had an especially bumpy go of it, with soaring high of a 14-1 panel approval and crushing low of an FDA complete response letter. Investors may be sick from the rollercoaster ride and are certainly looking for relief from the FDA. I want to provide a brief summary of what Krystexxa is, what it has gone through, and what I expect as we get closer to this important catalyst date.Complete Story » seekingalpha.com |
Celldex Reeling From Pfizer Breakup EP Vantage submits:The writing had been appearing on the wall in increasingly large red letters over Pfizer’s (PFE) commitment to Celldex Therapeutics’ (CLDX) brain cancer vaccine, rindopepimut (PF-04948568 / CDX-110) for some time now. Despite reporting decent if unspectacular phase IIb data at Asco this summer, Pfizer’s silence ever since over phase III plans was looking ominous (Event - Celldex hoping Asco data will move cancer vaccine into phase III, May 12, 2010).Nevertheless, all break-ups are painful when they finally happen and Celldex’s shares tumbled 26% on Friday to a record low of $3.53, valuing the Massachusetts biotech at just $113m despite it sitting on $65m in cash. Investors, unmoved by Celldex’s ambitious and positively spun response, are naturally more concerned about the reasons why Pfizer decided to ditch the vaccine and Celldex’s determination to go it alone with phase III trials, which will most likely need to be funded by dilutive financing.Complete Story » seekingalpha.com |
Genomic Health to Announce Third Quarter 2010 Financial Results and Host Conference Call on Monday, November 8, 2010 [PR Newswire] - Genomic Health, Inc. today announced that the company will host a conference call and webcast on Monday, November 8 at 4:30 p.m. Eastern Time to discuss its third quarter 2010 financial results. us.rd.yahoo.com |